Dr Reddy’s Lab launches generic eye treatment medication in US
PTI, Jan 27, 2023, 5:13 PM IST
Representative Image (Source: Pexels)
New Delhi: Dr Reddy’s Laboratories on Friday said it has launched Difluprednate Ophthalmic Emulsion, used in the treatment of pain and swelling in the eyes caused by infection or allergy after eye surgery, in the American market.
The company has launched the medication, a generic version of Durezol (Difluprednate Ophthalmic Emulsion 0.05 per cent) in the US market, after getting approval from the US Food and Drug Administration (USFDA), the Hyderabad-based drug major said in a statement.
As per IQVIA data, the Durezol brand and generics had sales of around USD 40 million in the US for the most recent twelve months ending in November 2022. Dr Reddy’s shares on Friday ended 2.78 percent up at Rs 4,321.35 apiece on the BSE.
Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.
Top News
Related Articles More
Markets surrender early gains to trade lower
US Fed interest rate decision key event to watch out for this week: Analysts
DGCA sticks to June 1 deadline for revised flight duty norms; says aim is to alleviate pilot fatigue
Govt approves 17% wage hike for 1.10 lakh employees of LIC
Air India lays off over 180 non-flying staff
MUST WATCH
Latest Additions
Tharoor slams CPI, says it is playing BJP’s game in Thiruvananthapuram
Messi out of Argentina friendlies in the US due to muscle injury
Gurugram Police to get production warrant for content creator Elvish Yadav in assault case
H1B initial registration period to close on March 22
Sullia: Naxal movement detected in Koojimale, say police sources